Darbepoetin alfa: potential role in managing anemia in cancer patients

References

• Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat. Rev26,303–311 (2000).
   PubMed Web of Science ®Google Scholar
• Groopman JE, Itri LM. Chemotherapy- induced anemia in adults: incidence and treatment. J. Nall Cancer Inst. 91, 1616–1634 (1999).
   PubMed Web of Science ®Google Scholar
• Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-associated anemia: the scope of the problem. Oncologist5\(Suppl. 2), 1–7 (2000).
   Google Scholar
• Ludwig H, Strasser K. Symptomatology of anemia. Semin. Oncol 28,7–14 (2001).
   PubMed Web of Science ®Google Scholar
• Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J. Clin. Oncol 19,3385–3391 (2001).
   PubMed Web of Science ®Google Scholar
• Grogan M, Thomas GM, Melamed I et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer86, 1528–1536 (1999).
   PubMed Web of Science ®Google Scholar
• Dubray B, Mosseri V, Brunin F et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology201,553–558 (1996).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91,2214–2221 (2001).
   PubMed Web of Science ®Google Scholar
• •First meta-analysis looking at anemia as an adverse prognostic indicator.
   Google Scholar
• Littlewood TJ, Bajetta E, Nortier J, Vercammen E, Rapoport B. Effects of epoetin-a on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind placebo-controlled trial. j Clin. Onco1.19, 2865–2874 (2001).
   Google Scholar
• •Indicates that epoetin may have a positive effect on survival in patients receiving chemotherapy.
   Google Scholar
• Glaser CM, Millesi W, Komek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol Phys. 50, 705–715 (2001). itLyman GH, Berndt E, Crown W Kallich J, Eider H, Finkelstein S. Anemia is associated with high cost in newly diagnosed cancer patients. Blood98\(Part 2), 414b (2001).
   Google Scholar
• Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. BE J. Cancer 84\(Suppl. 1), 31–37 (2001).
   Google Scholar
• Ortho Biotech. Epoetin-a (Procrit) package insert. Raritan, NJ, USA, (1999).
   Google Scholar
• Hoffmann-La Roche E Epoetin-I3(NeoRecormon) package insert. Basel, Switzerland (2000).
   Google Scholar
• Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin-a is independent of disease response or tumor type: results from a prospective community oncology study. Clin. arca 16, 3412–3425 (1998).
   Google Scholar
• Quirt I, Robeson C, Lau CY et al. Epoetin-a therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J. Clin. Oncol 19, 4126–4134 (2001).
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland C, Livingston RB, Sarokhan B, Winer E, Einhom L. Clinical evaluation of once-weekly dosing of epoetin-a in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times weekly dosing. J. Clin. Onco119, 2875–2882 (2001).
   Google Scholar
• •Demonstrates the feasibility of once-weekly dosing of epoetin.
   Google Scholar
• Abets R. Erythropoietin for anaemia in cancer patients. Eur J. Cancer 29A\(Suppl. 2), S2—S8 (1993).
   Google Scholar
• Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc. Natl Acad. Li. USA82,7580–7584 (1985).
   PubMed Web of Science ®Google Scholar
• EschbachjW Abdulhadi MN, Browne JK et al Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992–1000 (1989).
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin. Phatmacokinet. 20, 99–113 (1991).
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). BE j Cancer 84\(Suppl. 1), 3–10 (2001).
   Google Scholar
• •Interesting paper describing the development and preclinical testing of darbepoetin alfa.
   Google Scholar
• Bunn HE Pathophysiology of the anemias. In: Harrison's Principles and Practice of Internal Medicine (13th Edition). Isselbacher K (Ed.), McGraw-Hill, New York, NY, USA, 1717–1721 (1994).
   Google Scholar
• Dessypris EN. Erythropoiesis. In: Wintrobe's Clinical Hematology Lee GR, Foerster J, Lukens J et al (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA, 169–192 (1999).
   Google Scholar
• Glaspy J, Colowick AB, Heatherington A. Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half-life in oncology patients. Proc. Am. Soc. Clin. Oncol 19, 54a (2000).
   Google Scholar
• Heatherington AC, Schuller J, Mercer AJ, Rovetti RJ, Colowick AB. The pharmacokinetics of darbepoetin alfa administered subcutaneously in patients with non-myeloid malignancies receiving multicycle chemotherapy. B/ooc/98\(Part 1), 298a (2001).
   Google Scholar
• Heatherington A, Rovetti R, Kotasek D, Glaspy J, Colowick A. Predictability of pharmacokinetic properties of NESP administered once every 3 weeks in patients with nonmyeloid malignancies receiving cyclic chemotherapy. Proc. Am. Soc. Clin. Oncol 20, 119a (2001).
   Google Scholar
• Macdougall IC. Novel erythropoiesis stimulating protein. Sernin. Nephrol 20, 375–381 (2000).
   Web of Science ®Google Scholar
• Amgen Inc. Darbepoetin alfa (Aranesp) package insert. Thousand Oaks, CA, USA, (2001).
   Google Scholar
• Macdougall IC, Gray SJ, Elston 0 et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin-a in dialysis patients. j Am. Soc. Nephml. 10, 2392–2395 (1999).
   Google Scholar
• Heatherington A, Schuller J, Kotasek D et al Changes in endogenous erythropoietin and the pharmacokinetics of darbepoetin alfa in patients with nonmyeloid malignancies receiving or not receiving chemotherapy. Blood 98\(Part 1), 298a (2001).
   Google Scholar
• Pirker R, Vansteenkiste J, Gateley J, Yates P, Colowick A, Musil J. A Phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer. Eur Cancer37\(Suppl. 6), 264 (2001). Published Erratum appears in Eur. j Cancer 38, 449 (2002).
   Google Scholar
• Pirker R, Vansteenkiste J, Gateley J, Yates P, Colowick A, Musil J. A Phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer. Proc. Am. Soc. Clin. Oncol 20, 394a (2001).
   Google Scholar
• •• First published Phase III trial of darbepoetin alfa. Data presented at the 2001 Annual Meeting of ASCO also suggest that the time until disease progresses in patients receiving darbepoetin alfa may be prolonged compared with patients receiving placebo.
   Google Scholar
• Glaspy J, Jadeja J, Justice G et al Darbepoetin alfa administered every 1 or 2 weeks (with no loss of dose efficiency) alleviates anemia in patients with solid tumors. Blood 98 (Part 1), 298a (2001).
   Google Scholar
• ••Key study demonstrating that darbepoetinalfa is as effective when dosed every 2 weeks as once every week.
   Google Scholar
• Glaspy J, Jadeja J, Justice G et al Randomized, active-controlled, Phase VII, dose-escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors. Proc. Am. Soc. Clin. Oncol 20, 387a (2001).
   Google Scholar
• Hedenus M, Hansen S, Dewey C, Watson D, Colowick A, Osterborg A. A randomized, blinded, placebo-controlled, Phase II, dose-finding study of NESP in patients with lymphoproliferative malignancies. Proc. Am. Soc. Clin. Oncol 20, 393a (2001).
   Google Scholar
• Hedenus M, Glaspy J, Dewey C, O'Byrne J. Dose response of darbepoetin alfa is similar in anemic patients with solid tumors or lymphoproliferative malignancies. Blood 98\(Part 1), 297a (2001).
   Google Scholar
• Glaspy J, Jadeja J, Justice G et al Randomized, active-controlled, Phase VII, dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors. Eur. j Cancer 37 (Suppl. 6), 353 (2001).
   Google Scholar
• Kotasek D, Albertsson M, Mackey J et al Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3VV) or 4 (Q4VV) weeks in patients with solid tumors. Pmc. Am. Soc. Clin. Onto]. 21, 356a (2002).
   Google Scholar
• •First publication demonstrating feasibility of once every 3 and 4 weeks dosing of darbepoetin alfa.
   Google Scholar
• Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin. Oncol 21 (Suppl. 3), 21–28 (1994).
   Google Scholar
• Smith RE, Tchekmedyian NS, Chan D et al Open-label, Phase VII dose escalation study of NESP in patients with chronic anemia of cancer. Eur j Cancer 37 (Suppl. 6), 355 (2001).
   Google Scholar
• ••First study of darbepoetin alfa in patientswith cancer not receiving chemotherapy. Hemoglobin response observed in up to 92% of patients.
   Google Scholar
• Kallich J, Erder H, Glaspy J, Vansteenkiste J, Rossi G, Poulsen E. Improvement in haemoglobin levels improves health-related quality of life (HRQ0L) of anaemic cancer patients. iu:j Cancer37\(Suppl. 6), 441 (2001).
   Google Scholar
• Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. BE j Cancer 84 (Suppl. 1), 11–16 (2001).
   Google Scholar